TABLE 5

Topically administered therapeutic agents for back of the eye disorders in various preclinical models (Rodrigues et al., 2018)

CompoundFormulationPreclinical DataReference
TG100801SolutionMurine CNV model and edema in ratDoukas et al., 2008
PazopanibSolutionRat CNV modelYafai et al., 2011, Singh et al., 2014
AcrizanibSuspensionMurine CNVAdams et al., 2018
MemantineSolutionDrug levels in rabbit retinaHughes et al., 2005
DorzolamideSolutionDrug levels and carbonic anhydrase activity in corneal endothelial cells, ciliary body, lens epithelial cells, and retina in rabbitInoue et al., 2004
DexamethasoneIontophoresisDrug levels in retina and vitreous of rabbitAmbati and Adamis, 2002
BevacizumabSolutionDrug levels in iris/ciliary body, vitreous, retina/choroid, and plasma in rabbitAmbati et al., 2000a
Anti-intercellular adhesion molecule-1 antibodySolution by osmotic pumpDrug levels and VEGF-induced leukostasis in the choroid and retina in rabbitAmbati et al., 2000b
28-kD single-chain antibody fragmentSodium caprateDrug levels in vitreous in rabbitWilliams et al., 2005
BevacizumabAnnexin A5–based liposomesDrug levels in retina of rat and rabbitDavis et al., 2014
Transforming growth factor β1Annexin A5–based liposomesDrug levels in vitreous in rabbitPlatania et al., 2017
Acidic fibroblast growth factorCPP (TAT)Ischemia reperfusion model in ratWang et al., 2010
Calpain inhibitory peptideCPP (TAT)Drug levels in rabbit retinaOzaki et al., 2015
Green fluorescent proteinCPP (POD)Drug levels in mouse corneaJohnson et al., 2010
BevacizumabCPP (R6)Drug levels in vitreous and retina in rat and murine CNV modelde Cogan et al., 2017
  • CPP (R6), cell-penetrating peptide poly-arginine-6; POD, peptide of ocular delivery; TAT, transactivator of transcription.